Tumor-specific regulatory T cells suppress lytic granule release of adoptively transferred cytotoxic effector T cells and inhibit tumor rejection

2009 ◽  
Vol 47 (09) ◽  
Author(s):  
C Bauer ◽  
F Marangoni ◽  
T Murooka ◽  
N Elpak ◽  
TR Mempel
2009 ◽  
Vol 21 (4) ◽  
pp. 379-391 ◽  
Author(s):  
Kanji Nagahama ◽  
Zoltan Fehervari ◽  
Takatoku Oida ◽  
Tomoyuki Yamaguchi ◽  
Osamu Ogawa ◽  
...  

PLoS ONE ◽  
2016 ◽  
Vol 11 (6) ◽  
pp. e0157822 ◽  
Author(s):  
Nicolas Goudin ◽  
Pascal Chappert ◽  
Jérome Mégret ◽  
David-Alexandre Gross ◽  
Benedita Rocha ◽  
...  

2007 ◽  
Vol 178 (7) ◽  
pp. 4089-4096 ◽  
Author(s):  
Geordie Rudge ◽  
Simon P. Barrett ◽  
Bernadette Scott ◽  
Ian R. van Driel

2005 ◽  
Vol 202 (7) ◽  
pp. 885-891 ◽  
Author(s):  
Kuibeom Ko ◽  
Sayuri Yamazaki ◽  
Kyoko Nakamura ◽  
Tomohisa Nishioka ◽  
Keiji Hirota ◽  
...  

T cell stimulation via glucocorticoid-induced tumor necrosis factor receptor family–related protein (GITR) can evoke effective tumor immunity. A single administration of agonistic anti-GITR monoclonal antibody (mAb) to tumor-bearing mice intravenously or directly into tumors provoked potent tumor-specific immunity and eradicated established tumors without eliciting overt autoimmune disease. A large number of CD4+ and CD8+ T cells, including interferon (IFN)-γ–secreting cells, infiltrated regressing tumors. Tumor-specific IFN-γ–secreting CD4+ and CD8+ T cells also increased in the spleen. The treatment led to tumor rejection in IFN-γ–intact mice but not IFN-γ–deficient mice. Furthermore, coadministration of anti-GITR and anti–CTLA-4 mAbs had a synergistic effect, leading to eradication of more advanced tumors. In contrast, coadministration of anti-CD25 and anti-GITR mAbs was less effective than anti-GITR treatment alone, because anti-CD25 depleted both CD25+-activated effector T cells and CD25+CD4+ naturally occurring regulatory T (T reg) cells. Importantly, CD4+ T cells expressing the T reg–specific transcription factor Foxp3 predominantly infiltrated growing tumors in control mice, indicating that tumor-infiltrating natural Foxp3+CD25+CD4+ T reg cells may hamper the development of effective tumor immunity. Taken together, T cell stimulation through GITR attenuates T reg–mediated suppression or enhances tumor-killing by CD4+ and CD8+ effector T cells, including those secreting IFN-γ, or both. Agonistic anti-GITR mAb is therefore instrumental in treating advanced cancers.


Diabetologia ◽  
2008 ◽  
Vol 52 (3) ◽  
pp. 494-503 ◽  
Author(s):  
J. H. Velthuis ◽  
W. W. Unger ◽  
A. R. van der Slik ◽  
G. Duinkerken ◽  
M. Engelse ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document